BIOGEN INC. (BIIB) FY2024 Annual P&L / Income Statement

2024-01-01 to 2024-12-31

Swipe to see the full flow
BIOGEN INC. (BIIB) FY2024 Annual P&L / Income StatementIncome statement for 2024-01-01 through 2024-12-31. View: Product and service (Other Revenues). Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETRevenue from anti-CD20 therapeutic programsTYSABRI productSPINRAZARoyalty revenue on sales of OCREVUSTECFIDERAContract manufacturing, royalty and other revenueContract manufacturing revenueBENEPALIPLEGRIDYIMRALDIZURZUVAERoyalty and other revenueTOFIDENCERevenuesGross profit (calculated)Cost of sales, excluding amortization and impairment of acquired intangible assetsOperating profit (calculated)Operating expenses (calculated)Selling, general and administrativeResearch and developmentAmortization and impairment of acquired intangible assetsCollaboration profit sharing/(loss reimbursement)Gain on sale of priority review voucher, netRestructuring charges(Gain) loss on fair value remeasurement of contingent considerationOther (income) expense, netIncome before income tax (benefit) expense and equity in (income) loss of investee, net of taxNet incomeIncome tax (benefit) expenseGross profit (calculated)Gross profit(calculated)$7.37 BOperating profit (calculated)Operating profit(calculated)$1.91 BRevenuesRevenues$9.68 BIncome before income tax (benefit) expense and equity in (income) loss of investee, net of taxPretax income$1.91 BRevenue from anti-CD20 therapeutic programsRevenue from anti-CD20therapeutic programs$1.75 BNet incomeNet income$1.63 BOperating expenses (calculated)Operating expenses(calculated)$5.46 BTYSABRI productTYSABRI$1.72 BIncome tax (benefit) expenseIncome tax(benefit) expense$273.80 MSPINRAZASPINRAZA$1.57 BSelling, general and administrativeSelling, general and administrative$2.40 BRoyalty revenue on sales of OCREVUSRoyalty revenue on sales of OCREVUS$1.34 BResearch and developmentResearch and development$2.04 BCost of sales, excluding amortization and impairment of acquired intangible assetsCost of sales$2.31 BTECFIDERATECFIDERA$967.10 MAmortization and impairment of acquired intangible assetsAmortization and impairmentof acquired intangible assets$446.70 MContract manufacturing, royalty and other revenueContract manufacturing,royalty and other revenue$652.60 MCollaboration profit sharing/(loss reimbursement)Collaboration profitsharing/(loss reimbursement)$254.40 MContract manufacturing revenueContract manufacturing revenue$592.10 MGain on sale of priority review voucher, netGain on sale of priorityreview voucher, net−$88.60 MBENEPALIBENEPALI$479.10 MPLEGRIDYPLEGRIDY$260.50 MRestructuring chargesRestructuring charges$30.20 MIMRALDIIMRALDI$213.10 M(Gain) loss on fair value remeasurement of contingent consideration(Gain) loss on fairvalue remeasurement ofcontingent consideration$27.70 MZURZUVAEZURZUVAE$72.20 MRoyalty and other revenueRoyalty and other revenue$60.50 MOther (income) expense, netOther (income) expense, net$343.60 MTOFIDENCETOFIDENCE$1.10 M
Chart details

BIOGEN INC. (BIIB) FY2024 Annual P&L / Income Statement

Income statement for 2024-01-01 through 2024-12-31. View: Product and service (Other Revenues). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues
9,675,900,000 US dollars
Cost of sales, excluding amortization and impairment of acquired intangible assets
2,310,400,000 US dollars
Gross profit (calculated)
7,365,500,000 US dollars
Operating expenses (calculated)
5,459,500,000 US dollars
Operating profit (calculated)
1,906,000,000 US dollars
Other income (expense), net (calculated)
0 US dollars
Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax
1,906,000,000 US dollars
Income tax (benefit) expense
273,800,000 US dollars
Net income
1,632,200,000 US dollars
Contract manufacturing revenue
592,100,000 US dollars
Royalty and other revenue
60,500,000 US dollars
Contract manufacturing, royalty and other revenue
652,600,000 US dollars
BENEPALI
479,100,000 US dollars
IMRALDI
213,100,000 US dollars
PLEGRIDY
260,500,000 US dollars
Revenue from anti-CD20 therapeutic programs
1,749,900,000 US dollars
Royalty revenue on sales of OCREVUS
1,339,500,000 US dollars
SPINRAZA
1,573,200,000 US dollars
TECFIDERA
967,100,000 US dollars
TOFIDENCE
1,100,000 US dollars
TYSABRI product
1,715,000,000 US dollars
ZURZUVAE
72,200,000 US dollars
Research and development
2,041,800,000 US dollars
Selling, general and administrative
2,403,700,000 US dollars
Amortization and impairment of acquired intangible assets
446,700,000 US dollars
Gain on sale of priority review voucher, net
negative 88,600,000 US dollars
Collaboration profit sharing/(loss reimbursement)
254,400,000 US dollars
Gain on sale of building, net
0 US dollars
Other (income) expense, net
343,600,000 US dollars
(Gain) loss on fair value remeasurement of contingent consideration
27,700,000 US dollars
Restructuring charges
30,200,000 US dollars
Equity in (income) loss of investee, net of tax
0 US dollars. Reported below-tax contribution to net income.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.
BIOGEN INC. (BIIB) FY2024 Annual Revenue by Product and Service (3) Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

76.1%

Gross profit / revenue

Operating margin

19.7%

Operating profit / revenue

Cash conversion

176.2%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!